Somatostatin analogs (e.g., octreotide, lanreotide) will continue to be main therapies for functioning neuroendocrine tumors over the next years. Pasireotide, a new panreceptor analog, might ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

Jennifer Chan, MD, MPH, discussed the recent FDA approval of cabozantinib in pancreatic and extrapancreatic neuroendocrine tumors.

The approval came on the bases of the results from the phase 3 CABINET study. The study compared cabozantinib to a placebo in ...

The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients ...

Crinetics Pharma's Paltusotine shows strong Phase 3 results for acromegaly. Click here to find out why CRNX stock is a Buy.

Primary neuroendocrine carcinoma of the male breast is an exceptionally rare entity, with fewer than 50 cases documented in ...

The FDA approval was based on results from the CABINET study, a phase 3 pivotal trial evaluating cabozantinib compared with ...

The approval for use in advanced neuroendocrine tumors is supported by data from the phase 3 CABINET trial (ClinicalTrials.gov Identifier: NCT03375320). The double-blind, placebo-controlled study ...

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors ...

The FDA approved cabozantinib for previously treated, unresectable, locally advanced or metastatic, well-differentiated ...

With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer ...